PD-1 checkpoint inhibitor potentiating antibody therapy (Orega Biotech)

N/A

Report date: 2025/08/19 14:09:58

Base Information

Drug NamePD-1 checkpoint inhibitor potentiating antibody therapy (Orega Biotech)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionImmunostimulantsT lymphocytes stimulantsProgrammed cell death protein 1 blockers

TargetsProgrammed cell death protein 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOrega Biotech

China Registration ClassN/A

Develop Information

Active CompaniesOrega Biotech

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A